Investor Webinar recording
On 29 April 2025, Arovella CEO and MD, Dr Michael Baker, presented an investor webinar to provide an update following the release of the Company’s Appendix 4C quarterly while outlining next steps for Arovella throughout the rest of 2025 as it moves toward Phase 1 in-human trials.